Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| Krebsforschung Schweiz, Bern, Switzerland | OTHER |
Not provided
Not provided
Not provided
Not provided
This is a single center cross-sectional retrospective study with a quantitative and qualitative approach (phase 1 and 2). In phase 1 an online survey will be realized and targets male cancer survivors. Phase 2 will take a qualitative approach, in which information about patient's experiences, needs and helpful support will be collected by establishing focus groups of cancer patients who had been diagnosed during the reproductive age.
In the end, the results of this study will be integrated into the development of an online support tool concerning Fertility Preservation (FP).
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| online survey | Other | Part 1: online survey (quantitative) with questions on basic socio-demographic data, medical data and family characteristics (e.g. age, ethnicity, education) and information about FP. | ||
| focus group meeting | Other | Part 2: At the end of the online survey, participants are invited to attend one of the consecutively performed focus groups conducted according to standardized focus group methodology and moderated by a clinical psychologist and a specialist in reproductive medicine. |
| Measure | Description | Time Frame |
|---|---|---|
| male cancer patients level of information with regard to FP | Phase 1: exploratory online survey inquiring male cancer patients level of information with regard to FP | Phase 1 online survey at baseline |
| male cancer patients level of information with regard to FP | Phase 2: interview (strictly exploratory) in focus groups collecting data on male cancer patients level of information with regard to FP | Phase 2 focus group meeting (approx. 2 to 4 weeks after baseline) |
| Measure | Description | Time Frame |
|---|---|---|
| male cancer patients needs regarding decision-making about FP | exploratory online survey inquiring which kind of support regarding decision-making about FP do male cancer patients consider helpful | Phase 1 online survey at baseline |
| male cancer patients expectation with regard to an online DA tool about FP |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Cancer patients who are/were possible candidates for FP (patients with fertility compromising cancer treatment) will be invited to participate. Eligible patients will be approached by their former or current treating oncologist, urologist or specialist in reproductive medicine.
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Sibil Tschudin, PD Dr. med | Frauenklinik Universitätsspital Basel | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Frauenklinik University Hospital Basel | Basel | 4031 | Switzerland |
Not provided
| ID | Term |
|---|---|
| D009369 | Neoplasms |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
exploratory online survey inquiring how an online Decision Aid (DA) tool about FP has to be designed in order to be helpful for male cancer patients |
| Phase 1 online survey at baseline |
| male cancer patients needs regarding decision-making about FP | Phase 2: interview (strictly exploratory) in focus groups evaluating which kind of support regarding decision-making about FP male cancer patients consider helpful | Phase 2 focus group meeting (approx. 2 to 4 weeks after baseline) |
| male cancer patients expectation with regard to an online DA tool about FP | Phase 2: interview (strictly exploratory) in focus groups evaluating how an online DA tool about FP has to be designed in order to be helpful for male cancer patients | Phase 2 focus group meeting (approx. 2 to 4 weeks after baseline) |